Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Department of Immunology, University of Washington, Seattle, WA, United States.
Curr Opin Immunol. 2022 Feb;74:9-17. doi: 10.1016/j.coi.2021.09.003. Epub 2021 Sep 24.
Adoptive cell therapy with T cells engineered with customized receptors that redirect antigen specificity to cancer cells has emerged as an effective therapeutic approach for many malignancies. Toxicity due to on target or off target effects, antigen heterogeneity on cancer cells, and acquired T cell dysfunction have been identified as barriers that can hinder successful therapy. This review will discuss recent advances in T cell engineering that have enabled the application of logic gates in T cells that can mimic the integration of natural signaling pathways and act in a cell intrinsic or extrinsic fashion to precisely target tumor cells and regulate effector functions, potentially overcoming these barriers to effective therapy.
采用经过基因工程改造的受体定向重定向抗原特异性的 T 细胞的过继细胞疗法已成为治疗多种恶性肿瘤的有效方法。由于靶向或脱靶效应、癌细胞上的抗原异质性以及获得性 T 细胞功能障碍,已经确定了可能阻碍成功治疗的障碍。这篇综述将讨论 T 细胞工程的最新进展,这些进展使逻辑门能够在 T 细胞中应用,从而模拟自然信号通路的整合,并以细胞内或细胞外的方式精确靶向肿瘤细胞并调节效应功能,从而有可能克服这些障碍,实现有效的治疗。